How to Fight Insurance Denials for Stroke Rehabilitation: A Patient's Guide

Every year, 800,000 Americans experience a stroke. Recovery is not linear, it does not end at six months, and it requires access to specialized rehabilitation—inpatient rehab facilities (IRFs), outpatient physical and occupational therapy, speech-language pathology, robotic gait training, constraint-induced movement therapy (CIMT), and Botox for spasticity management. Yet insurance companies routinely deny coverage for these treatments, citing obsolete time windows, arbitrary visit caps that Congress repealed years ago, or blanket "experimental" labels for therapies supported by peer-reviewed trials. This guide explains why insurers deny stroke rehab, which clinical evidence and policy citations carry weight, and how to structure an appeal that wins.

Why Insurers Deny Stroke Rehabilitation

1. "Patient is outside the acute treatment window"

Insurers deny IV alteplase (tPA) beyond 4.5 hours or mechanical thrombectomy beyond 6 hours, ignoring landmark trials that extended the window to 24 hours for carefully selected patients with imaging-confirmed viable brain tissue.

2. "Inpatient rehab is not medically necessary; skilled nursing facility (SNF) is appropriate"

Payers push stroke survivors into SNFs instead of IRFs to save money, claiming the patient doesn't need the intensity of IRF-level care—even when stroke is a qualifying diagnosis under Medicare's 60% Rule, which mandates that 60% of an IRF's patients come from 13 qualifying conditions, including stroke.

3. "Outpatient therapy cap reached / no additional visits authorized"

Despite Congress repealing the Medicare therapy cap in 2018, many Medicare Advantage plans and commercial insurers still impose arbitrary visit limits (often 20–30 visits per year) and deny further therapy, citing "plateau" or lack of ongoing functional gains.

4. "Robotic gait training / CIMT / FES is experimental or investigational"

Insurers label robotic-assisted gait therapy (Lokomat, Indego, EksoNR), constraint-induced movement therapy, and functional electrical stimulation (Bioness L300, NESS H200) as unproven, even when published trials and FDA clearances exist.

5. "Botox for spasticity is cosmetic or off-label"

Botulinum toxin (Botox, Dysport, Xeomin) for post-stroke spasticity is FDA-approved for upper-limb (March 2010) and lower-limb (January 2016) indications, yet insurers sometimes deny it as "cosmetic" or require exhaustive documentation of failed conservative therapy.

The Citations Insurers Respect

When appealing, you must speak the language of evidence-based medicine. Generic appeals fail. The following studies, guidelines, and policies carry weight:

Acute Reperfusion

• DAWN trial (DWI or CTP Assessment with Clinical Mismatch in the Triage of Wake-Up and Late Presenting Strokes Undergoing Neurointervention with Trevo, NEJM 2018): Extended mechanical thrombectomy to 6–24 hours for large-vessel occlusion (LVO) with imaging-selected patients (ASPECTS, core-penumbra mismatch).
• DEFUSE-3 trial (NEJM 2018): Confirmed benefit of thrombectomy 6–16 hours post-onset in patients with favorable perfusion imaging.
• AHA/ASA 2019 Guidelines (updated from 2018): Recommend mechanical thrombectomy up to 24 hours in selected patients meeting DAWN/DEFUSE-3 criteria.

Inpatient Rehabilitation Facility (IRF) Admission

• Medicare's 60% Rule (CMS): Stroke is one of 13 qualifying conditions; IRFs must admit at least 60% of patients from this list. Stroke survivors are presumptively appropriate for IRF if they can tolerate 3 hours of therapy per day, five days per week.
• CMS Inpatient Rehabilitation Facility Medical Review Criteria (CMS-1500 / IRF-PAI documentation): Requires physician face-to-face, documented rehabilitation goals, and multidisciplinary team plan.

Outpatient Therapy

• Bipartisan Budget Act of 2018 (Pub. L. 115-123): Repealed the Medicare therapy cap (previously $2,010 per discipline annually). Therapy is now unlimited if medically necessary, with a KX modifier threshold ($2,330 in 2024) triggering targeted medical review—not an automatic denial.
• LEAPS trial (NEJM 2011, Duncan et al.): Locomotor Experience Applied Post-Stroke. Randomized controlled trial of task-specific gait training vs. home exercise in chronic stroke (>6 months). Showed improvement even in the chronic phase, contradicting the notion that recovery plateaus at six months.

Constraint-Induced Movement Therapy (CIMT)

• EXCITE trial (JAMA 2006, Wolf et al.): Extremity Constraint-Induced Therapy Evaluation. Demonstrated durable motor gains with Taub protocol (6 hours/day, 2 weeks) in chronic stroke (3–9 months post).
• Modified CIMT (mCIMT) protocols (3 hours/day, 10 weeks) are widely documented in clinical practice guidelines and replicated in multiple smaller trials.

Robotic Gait Training

• LEAPS trial (NEJM 2011): While not specifically robotic, established that locomotor training in chronic stroke is effective.
• Cochrane Review 2020 (Mehrholz et al., "Electromechanical-assisted training for walking after stroke"): Meta-analysis showing robotic-assisted gait training increases the odds of independent walking.
• FDA clearances: Lokomat (FDA 510(k) K061888), Indego (K151295), EksoNR (K143326) all cleared for stroke rehabilitation; FDA clearance refutes "experimental" claims.

Botulinum Toxin for Spasticity

• Botox FDA approval: Upper-limb spasticity (March 2010, BLA 103000/S-5259), lower-limb spasticity (January 2016, S-5274).
• AAN/AANEM 2016 Guideline Update (Neurology 2016, Simpson et al.): Rates botulinum toxin Level A evidence for upper- and lower-limb post-stroke spasticity.
• Dysport and Xeomin also FDA-approved for upper-limb post-stroke spasticity.

Functional Electrical Stimulation (FES)

• Bioness L300 for foot drop (FDA K060692) and NESS H200 for hand function (K011520): FDA-cleared, not experimental.
• Cochrane Review 2013 (Pomeroy et al.): Supported FES for improving gait speed and functional ambulation post-stroke.

Dysphagia Therapy

• VitalStim NMES (neuromuscular electrical stimulation for swallowing): FDA-cleared (K013519), though evidence is mixed; most insurers will cover traditional dysphagia therapy (modified barium swallow study, MBSS, fiberoptic endoscopic evaluation of swallowing, FEES) without controversy.
• McNeill Dysphagia Therapy Program (MDTP) and traditional speech-language pathology swallowing protocols: Standard of care.

Cognitive Rehabilitation (Aphasia, Neglect)

• Constraint-Induced Aphasia Therapy (CIAT) and Melodic Intonation Therapy (MIT): Evidence base in Stroke and Brain journals; standard in neuropsychology and speech-language pathology practice.
• Prism adaptation for neglect: Documented in Stroke 2006 (Frassinetti et al.) and subsequent replication studies.

How to Argue Against Each Denial Reason

1. "Patient is outside the acute treatment window"

If you are denied tPA or thrombectomy:

• Pull the imaging. If you had CT angiography (CTA), CT perfusion (CTP), or MRI with diffusion-weighted imaging (DWI) and perfusion-weighted imaging (PWI), request the radiology report. Look for documented core infarct size (ASPECTS score), penumbra volume, and mismatch ratio.
• Cite DAWN and DEFUSE-3 by name. Include the NEJM 2018 citations. State: "The AHA/ASA 2019 Guidelines (updated 2018) recommend mechanical thrombectomy up to 24 hours in patients meeting DAWN or DEFUSE-3 imaging criteria—core-penumbra mismatch and ASPECTS ≥6."
• Document your NIHSS. The National Institutes of Health Stroke Scale (NIHSS) at admission quantifies stroke severity. Moderate-to-severe stroke (NIHSS ≥6) with imaging mismatch is the sweet spot for extended-window thrombectomy.
• If you are still within 24 hours, ask your neurologist or interventionalist to submit a peer-to-peer review request with the insurer's medical director, armed with the imaging and the AHA/ASA guideline pages.

Sample appeal language:

> "The denial cites a 6-hour thrombectomy window. This is outdated. The DAWN trial (NEJM 2018, Nogueira et al.) and DEFUSE-3 trial (NEJM 2018, Albers et al.) demonstrated benefit of mechanical thrombectomy 6–24 hours post-onset in imaging-selected patients. The AHA/ASA 2019 Guidelines (Class I, Level A evidence) recommend thrombectomy up to 24 hours for large-vessel occlusion with favorable perfusion imaging. My CTA showed left MCA M1 occlusion, ASPECTS 8, and CTP demonstrated 80 mL core with 150 mL penumbra—mismatch ratio 1.9. I presented at 8 hours. I met DAWN criteria and was eligible for thrombectomy."

2. "IRF is not medically necessary; SNF is appropriate"

If you are denied IRF admission:

• Invoke the 60% Rule. Stroke is a qualifying diagnosis under CMS regulations. State: "Stroke is one of 13 conditions listed in Medicare's 60% Rule (42 CFR §412.29(b)(2)). I am presumptively appropriate for IRF admission."
• Document your tolerance for intensive therapy. IRF requires 3 hours of therapy per day, 5 days per week. If your physician and therapy team have documented that you can participate—even with moderate hemiparesis or aphasia—cite this in your appeal.
• Highlight functional goals. IRFs are for patients with rehabilitation potential and specific, measurable goals: ambulation distance, Activities of Daily Living (ADL) independence (Barthel Index, Functional Independence Measure/FIM), return-to-work timelines.
• SNF is insufficient. SNF provides 1–2 hours of therapy per day, often in a long-term care environment without the interdisciplinary intensity of IRF (physiatrist, neurologist, speech-language pathologist, occupational therapist, physical therapist, rehab nurse, case manager, neuropsychologist).

Sample appeal language:

> "The denial states SNF is 'appropriate' without addressing why IRF is not. I am a 52-year-old software developer, three weeks post-stroke (left MCA, NIHSS 18 at admission, current 8). My modified Rankin Scale (mRS) was 0 pre-stroke; it is now 3. I can tolerate 3 hours of therapy per day, as documented by my physiatrist. My Barthel Index is 65 (moderate impairment), FIM 78. My goals: independent ADLs, return to 80% telework within 3 months, and eventual driving resumption. Stroke is a qualifying diagnosis under Medicare's 60% Rule (42 CFR §412.29(b)(2)). SNF provides insufficient therapy intensity (1–2 hr/day) for a working-age patient with high rehabilitation potential. I request IRF admission per CMS Inpatient Rehabilitation Facility Medical Review Criteria."

3. "Outpatient therapy cap reached / no additional visits authorized"

If you are denied continued outpatient PT, OT, or SLP:

• The therapy cap was repealed in 2018. Congress eliminated the Medicare therapy cap with the Bipartisan Budget Act of 2018. There is no annual dollar limit. State this explicitly.
• The KX modifier threshold is not a cap. In 2024, the threshold is $2,330 per discipline (PT, OT, SLP). Exceeding this triggers targeted medical review—it does not automatically deny coverage. Your therapist must document continued functional improvement or maintenance to prevent decline.
• Cite LEAPS. The NEJM 2011 trial showed improvement in chronic stroke (>6 months). If you are in the chronic phase and your insurer claims you've "plateaued," LEAPS refutes that dogma.
• Document objective measures. If your 10-Meter Walk Test improved from 0.4 m/s to 0.6 m/s, or your Berg Balance Scale rose from 35 to 42, or your Action Research Arm Test (ARAT) score increased, include these numbers. If you have not plateaued, say so. If you have plateaued but therapy is maintenance to prevent decline (e.g., preventing contracture, maintaining gait speed for community ambulation), Medicare covers maintenance therapy per Jimmo v. Sebelius (2013 settlement).

Sample appeal language:

> "The denial cites '20-visit cap exceeded.' This is factually incorrect. The Medicare therapy cap was repealed by the Bipartisan Budget Act of 2018 (Pub. L. 115-123). There is no annual visit limit. The $2,330 KX modifier threshold is not a cap; it triggers additional documentation, which my therapist has provided. I am three months post-stroke. My 10-Meter Walk Test has improved from 0.4 m/s (household ambulator) to 0.6 m/s (limited community ambulator) over 18 visits, and my goal is 0.8 m/s for full community ambulation. The LEAPS trial (NEJM 2011, Duncan et al.) demonstrated continued functional gains in chronic stroke with task-specific training. I have not plateaued and request authorization for an additional 12 visits."

4. "Robotic gait training / CIMT / FES is experimental or investigational"

If you are denied robotic therapy, CIMT, or FES:

• FDA clearance refutes "experimental." Lokomat, Indego, EksoNR, Bioness L300, and NESS H200 all have FDA 510(k) clearances for stroke rehabilitation. List the clearance numbers in your appeal.
• Cite the Cochrane Review 2020 for robotic gait (Mehrholz et al., "Electromechanical-assisted training for walking after stroke"): Meta-analysis of 62 trials, 2440 participants. Robotic-assisted gait training increased the odds of independent walking (OR 1.94, 95% CI 1.39–2.71).
• Cite EXCITE (JAMA 2006) for CIMT: Randomized controlled trial, 222 participants, durable motor improvement in chronic stroke (3–9 months post).
• Request peer-to-peer review. Many insurers reverse "experimental" denials when a physiatrist or neurologist explains the evidence directly to the plan's medical director.

Sample appeal language (robotic gait):

> "The denial labels Lokomat as 'experimental.' Lokomat received FDA 510(k) clearance (K061888) in 2006 for gait rehabilitation in stroke and spinal cord injury. The Cochrane Review 2020 (Mehrholz et al., 'Electromechanical-assisted training for walking after stroke') analyzed 62 trials and 2440 participants, concluding that robotic-assisted gait training significantly increases the likelihood of independent walking (OR 1.94). The LEAPS trial (NEJM 2011) showed that task-specific locomotor training improves gait speed even in chronic stroke. I am five months post-stroke, ambulatory with AFO and cane, and my goal is independent community ambulation. I request authorization for 24 sessions of robotic-assisted gait training."

Sample appeal language (CIMT):

> "The denial states CIMT is 'not proven effective.' The EXCITE trial (JAMA 2006, Wolf et al.) was a randomized controlled trial of 222 chronic stroke patients (3–9 months post) showing significant, durable improvement in upper-extremity function with the Taub CIMT protocol (6 hr/day, 2 weeks). Modified CIMT (mCIMT, 3 hr/day, 10 weeks) is documented in multiple trials and is standard care in academic stroke centers. My Fugl-Meyer Upper-Extremity score is 28/66 (moderate impairment). I have measurable motor recovery potential. I request authorization for a 10-week mCIMT program."

5. "Botox for spasticity is cosmetic or off-label"

If you are denied Botox (or Dysport, Xeomin):

• FDA approval dates. Botox was approved for upper-limb post-stroke spasticity in March 2010 and lower-limb in January 2016. This is not off-label.
• Cite the AAN/AANEM 2016 Guideline. The American Academy of Neurology and American Association of Neuromuscular & Electrodiagnostic Medicine rate botulinum toxin Level A evidence for upper- and lower-limb spasticity (Neurology 2016, Simpson et al.).
• Document functional impairment. Spasticity must interfere with function (e.g., hygiene of clenched fist, gait, positioning in wheelchair) or cause pain. If you have Modified Ashworth Scale (MAS) scores ≥2, include them. If you have failed conservative measures (stretching, splinting, oral baclofen or tizanidine), document that.
• Not cosmetic. If Botox is for cosmetic wrinkles, insurers can deny. If it is for spasticity reducing your ability to dress, bathe, walk, or causing pain, it is medical.

Sample appeal language:

> "The denial claims Botox is 'cosmetic.' I am requesting onabotulinumtoxinA (Botox) for upper-limb post-stroke spasticity, an FDA-approved indication (BLA 103000/S-5259, March 2010). The AAN/AANEM 2016 Guideline Update (Neurology 2016, Simpson et al.) rates botulinum toxin Level A evidence for post-stroke upper-limb spasticity. My Modified Ashworth Scale scores: elbow flexors 3, wrist flexors 2+, finger flexors 3. Spasticity prevents hand hygiene and functional grasp. I have completed 8 weeks of stretching and splinting without improvement and cannot tolerate oral baclofen (sedation). I request authorization for Botox 200 units to elbow, wrist, and finger flexors, with post-injection therapy."

What We Do

We are medical billing advocates and former clinicians who write comprehensive, evidence-based appeal letters for stroke survivors. We pull your clinical records, imaging reports, therapy notes, and functional assessments; we cite the specific trials, guidelines, and FDA clearances that insurers cannot ignore; and we translate your story into the language of medical necessity. We handle expedited appeals when deadlines are tight (72 hours for urgent, 30 days for standard) and coordinate peer-to-peer reviews with your physicians. Our goal is not to write generic form letters—it is to build an irrefutable case rooted in the clinical literature and your documented rehabilitation potential.

Sources

1. Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct. N Engl J Med. 2018;378(11):​1-12. (DAWN trial)

2. Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging. N Engl J Med. 2018;378(8):​708-718. (DEFUSE-3 trial)

3. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 2019;50(12):​e344-e418. (AHA/ASA 2019)

4. U.S. Centers for Medicare & Medicaid Services. Inpatient Rehabilitation Facility Prospective Payment System: 60% Rule. 42 CFR §412.29(b)(2).

5. Bipartisan Budget Act of 2018, Pub. L. No. 115-123, §50202 (repealing Medicare therapy cap).

6. Duncan PW, Sullivan KJ, Behrman AL, et al. Body-Weight–Supported Treadmill Rehabilitation after Stroke. N Engl J Med. 2011;364(21):​2026-2036. (LEAPS trial)

7. Wolf SL, Winstein CJ, Miller JP, et al. Effect of Constraint-Induced Movement Therapy on Upper Extremity Function 3 to 9 Months After Stroke: The EXCITE Randomized Clinical Trial. JAMA. 2006;296(17):​2095-2104.

8. Mehrholz J, Thomas S, Kugler J, Pohl M, Elsner B. Electromechanical-assisted training for walking after stroke. Cochrane Database Syst Rev. 2020;10:CD006185.

9. U.S. Food and Drug Administration. 510(k) Premarket Notification Database: Lokomat (K061888), Indego (K151295), EksoNR (K143326), Bioness L300 (K060692), NESS H200 (K011520).

10. OnabotulinumtoxinA (Botox) Prescribing Information. FDA BLA 103000/S-5259 (upper-limb spasticity, March 2010); S-5274 (lower-limb spasticity, January 2016).

11. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache. Neurology. 2016;86(19):​1818-1826. (AAN/AANEM 2016)

12. Pomeroy VM, King L, Pollock A, Baily-Hallam A, Langhorne P. Electrostimulation for promoting recovery of movement or functional ability after stroke. Cochrane Database Syst Rev. 2006;(2):CD003241.

13. Jimmo v. Sebelius, No. 5:11-cv-00017 (D. Vt. settlement Jan. 24, 2013) (maintenance therapy coverage under Medicare).

14. Frassinetti F, Angeli V, Meneghello F, Avanzi S, Làdavas E. Long-lasting amelioration of visuospatial neglect by prism adaptation. Brain. 2002;125(Pt 3):608-623.